Guangxi Wuzhou Zhongheng GroupLtd Past Earnings Performance
Past criteria checks 1/6
Guangxi Wuzhou Zhongheng GroupLtd's earnings have been declining at an average annual rate of -43.3%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been declining at an average rate of 6.8% per year. Guangxi Wuzhou Zhongheng GroupLtd's return on equity is 1.3%, and it has net margins of 4.8%.
Key information
-43.3%
Earnings growth rate
-43.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -6.8% |
| Return on equity | 1.3% |
| Net Margin | 4.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Guangxi Wuzhou Zhongheng GroupLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 3,233 | 156 | 1,574 | 154 |
| 31 Dec 23 | 3,097 | 84 | 1,714 | 154 |
| 30 Sep 23 | 2,989 | 54 | 1,599 | 126 |
| 30 Jun 23 | 3,003 | 59 | 1,643 | 128 |
| 31 Mar 23 | 2,743 | -24 | 1,554 | 114 |
| 31 Dec 22 | 2,714 | 79 | 1,445 | 135 |
| 30 Sep 22 | 2,383 | -68 | 1,574 | 197 |
| 30 Jun 22 | 2,469 | 70 | 1,557 | 202 |
| 31 Mar 22 | 2,648 | 212 | 1,590 | 215 |
| 31 Dec 21 | 3,162 | 307 | 1,995 | 198 |
| 30 Sep 21 | 3,419 | 656 | 2,342 | 190 |
| 30 Jun 21 | 3,812 | 590 | 2,643 | 173 |
| 31 Mar 21 | 3,847 | 588 | 2,663 | 152 |
| 31 Dec 20 | 3,676 | 563 | 2,326 | 132 |
| 30 Sep 20 | 3,988 | 596 | 2,150 | 57 |
| 30 Jun 20 | 3,747 | 700 | 1,989 | 52 |
| 31 Mar 20 | 3,923 | 727 | 2,187 | 53 |
| 31 Dec 19 | 3,814 | 745 | 2,438 | 63 |
| 30 Sep 19 | 3,589 | 713 | 2,488 | 37 |
| 30 Jun 19 | 3,602 | 640 | 2,558 | 38 |
| 31 Mar 19 | 3,508 | 669 | 2,496 | 51 |
| 31 Dec 18 | 3,299 | 613 | 2,296 | 45 |
| 30 Sep 18 | 2,913 | 552 | 1,950 | 52 |
| 30 Jun 18 | 2,624 | 555 | 1,600 | 88 |
| 31 Mar 18 | 2,305 | 577 | 1,199 | 59 |
| 31 Dec 17 | 2,048 | 605 | 885 | 47 |
| 30 Sep 17 | 2,153 | 587 | 895 | 50 |
| 30 Jun 17 | 1,880 | 596 | 676 | 0 |
| 31 Mar 17 | 1,734 | 496 | 574 | 0 |
| 31 Dec 16 | 1,670 | 489 | 532 | 0 |
| 30 Sep 16 | 1,172 | 354 | 348 | 0 |
| 30 Jun 16 | 1,016 | 181 | 395 | 0 |
| 31 Mar 16 | 997 | 440 | 503 | 0 |
| 31 Dec 15 | 1,343 | 520 | 669 | 0 |
| 30 Sep 15 | 1,878 | 1,457 | 740 | 0 |
| 30 Jun 15 | 2,473 | 1,723 | 960 | 0 |
| 31 Mar 15 | 3,027 | 1,615 | 1,158 | 0 |
| 31 Dec 14 | 3,214 | 1,595 | 1,370 | 0 |
| 30 Sep 14 | 3,613 | 920 | 1,692 | 0 |
| 30 Jun 14 | 4,236 | 859 | 2,366 | 0 |
| 31 Mar 14 | 4,245 | 815 | 2,440 | 0 |
| 31 Dec 13 | 3,997 | 743 | 2,327 | 0 |
| 30 Sep 13 | 3,768 | 809 | 2,137 | 0 |
| 30 Jun 13 | 2,803 | 735 | 1,314 | 0 |
Quality Earnings: 600252 has a large one-off loss of CN¥77.5M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 600252 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600252's earnings have declined by 43.3% per year over the past 5 years.
Accelerating Growth: 600252 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 600252 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.5%).
Return on Equity
High ROE: 600252's Return on Equity (1.3%) is considered low.